
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Shares | 100.00 | 100.00 | 0.00 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 14.30 | 18.84 |
Price to Book | 3.18 | 4.28 |
Price to Sales | 2.17 | 2.30 |
Price to Cash Flow | 12.19 | 15.61 |
Dividend Yield | 1.94 | 1.18 |
5 Years Earnings Growth | 9.18 | 11.02 |
Name | Net % | Category Average |
---|---|---|
Healthcare | 95.12 | 99.59 |
Financial Services | 3.38 | 0.73 |
Consumer Defensive | 0.68 | 0.48 |
Communication Services | 0.60 | 0.65 |
Basic Materials | 0.15 | 1.02 |
Technology | 0.06 | 0.17 |
Number of long holdings: 108
Number of short holdings: 2
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Eli Lilly | US5324571083 | 8.60 | 762.33 | +3.01% | |
Boston Scientific | US1011371077 | 6.14 | 105.41 | +0.47% | |
Pfizer | US7170811035 | 4.13 | 23.49 | +0.86% | |
Chugai Pharmaceutical | JP3519400000 | 4.04 | 7,322.0 | -0.25% | |
Roche Holding Participation | CH0012032048 | 3.71 | 257.10 | -0.96% | |
AbbVie | US00287Y1091 | 3.71 | 195.22 | +3.28% | |
Elevance Health | US0367521038 | 3.71 | 274.66 | -2.97% | |
Merck&Co | US58933Y1055 | 3.65 | 79.29 | +1.50% | |
Gilead | US3755581036 | 3.55 | 113.18 | +0.79% | |
Amgen | US0311621009 | 3.54 | 296.88 | +0.60% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Delaware Small Cap Core I | 4.74B | -3.72 | 8.03 | 7.66 | ||
Delaware Emerging Markets Instl | 3.1B | 30.80 | 15.69 | 7.85 | ||
Delaware Small Cap Value Instl | 1.82B | -0.26 | 8.70 | 7.31 | ||
Optimum Large Cap Growth Instl | 1.95B | 4.30 | 24.24 | 13.46 | ||
Optimum Large Cap Value Instl | 1.82B | 6.20 | 12.74 | 8.86 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review